Squamous Non-Small Cell Lung Cancer Therapeutics Market 2025: Industry Developments, Future Growth, Share & Industry Insights

Global Squamous Non-Small Cell Lung Cancer Therapeutics Market reached US$4 billion in 2023 and is expected to reach US$ 8.06 billion by 2031, growing at a CAGR of 9.4% during the forecast period 2024-2031.

DataM Intelligence has published a new research report on "Squamous Non-Small Cell Lung Cancer Therapeutics Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/squamous-non-small-cell-lung-cancer-therapeutics-market?sg

Key Players: Genentech, Bristol Myers Squibb, Eli Lilly and Company, AstraZeneca, Pfizer Inc., Novartis AG, Merck Sharp & Dhome Corporation, Breckenridge Pharmaceutical Inc., Teva Pharmaceuticals Inc and Apotex Corporation.

Product Launches & Approvals:

✅ FDA Approves Datroway for EGFR-Mutated NSCLC
On June 24, 2025, the FDA approved Datroway, an antibody-drug conjugate developed by AstraZeneca and Daiichi Sankyo, for treating advanced non-small cell lung cancer with EGFR mutations.

✅ FDA Clears IND for IBI363 in Squamous NSCLC
On August 25, 2025, the FDA cleared the Investigational New Drug (IND) application for IBI363, a bispecific antibody fusion protein targeting PD-1 and IL-2α, for squamous non-small cell lung cancer.

✅ FDA Grants Breakthrough Therapy Designation to Izalontamab Brengitecan
On August 18, 2025, the FDA granted Breakthrough Therapy Designation to Izalontamab Brengitecan (EGFRxHER3 ADC) for patients with previously treated advanced EGFR-mutated non-small cell lung cancer.

✅ FDA Grants Breakthrough Therapy Designation to Ifinatamab Deruxtecan
On August 18, 2025, the FDA granted Breakthrough Therapy Designation to Ifinatamab Deruxtecan for patients with pretreated extensive-stage small cell lung cancer.

Mergers & Acquisitions:

✅ Sun Pharma Acquires Checkpoint Therapeutics for $355 Million
On March 10, 2025, Sun Pharmaceutical Industries announced its acquisition of Checkpoint Therapeutics, adding the FDA-approved immunotherapy UNLOXCYT to its oncology portfolio.

✅ Bristol Myers Squibb Signs $11 Billion Deal with BioNTech
On June 15, 2025, Bristol Myers Squibb entered into an $11 billion partnership with BioNTech to co-develop and commercialize BNT327, a bispecific antibody targeting two cancer cell receptors simultaneously.

✅ Pfizer Inks Up to $6 Billion Deal with 3SBio for Cancer Drug
On May 5, 2025, Pfizer entered into a licensing agreement with Chinese pharmaceutical company 3SBio to develop and commercialize the cancer drug SSGJ-707 outside of China.

Strategic Partnerships & Collaborations:

✅ Takeda Partners with Innovent Biologics on Oncology Drugs
On October 21, 2025, Takeda announced a strategic partnership with Innovent Biologics to co-develop and commercialize two late-stage oncology medicines, IBI363 and IBI343, worldwide outside of Greater China.

✅ Johnson & Johnson Enters New Era in Solid Tumors at ESMO 2025
On October 15, 2025, Johnson & Johnson presented promising data on subcutaneous amivantamab across multiple tumor types, including non-small cell lung cancer, at ESMO 2025.

Growth Forecast Projected:

The Global Squamous Non-Small Cell Lung Cancer Therapeutics Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Squamous Non-Small Cell Lung Cancer Therapeutics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=squamous-non-small-cell-lung-cancer-therapeutics-market?sg

Key Segments:

By Therapy type (Targeted Therapy, Immunotherapy, Chemotherapy, Others)

By End-User (Hospitals, Specialty Clinics, Others)

By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Squamous Non-Small Cell Lung Cancer Therapeutics producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Squamous Non-Small Cell Lung Cancer Therapeutics revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/squamous-non-small-cell-lung-cancer-therapeutics-market?sg

FAQ's

Q1: What is the current size of the Squamous Non-Small Cell Lung Cancer Therapeutics Market?

A: The Squamous Non-Small Cell Lung Cancer Therapeutics Market stood at US$4 billion in 2023 and is set to experience remarkable growth, reaching US$ 8.06 billion by 2031

Q2: How fast is the Squamous Non-Small Cell Lung Cancer Therapeutics Market growing?

A: The Market is on an impressive growth trajectory, expected to expand at a CAGR of 9.4% from 2024-2031.

Have any Enquiry of This Report @ https://www.datamintelligence.com/enquiry/squamous-non-small-cell-lung-cancer-therapeutics-market?sg

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.